BACKGROUND: Renal cell carcinoma (RCC) is the sixth leading cause of death in
developed countries. A third of all RCC patients are confronted with metastatic disease …

Conclusion Whatever the modest progress made for a small number of patients with MRCC,
the majority of patients will die within 5 years of diagnosis of MRCC. Therefore, there is a …

Background The real-world survival outcomes and prognostic factors among patients
receiving first-line targeted therapy for advanced renal cell carcinoma (aRCC) are not well …

The spectrum of drugs that have shown activity in advanced or metastatic renal cell
carcinoma (RCC) has led to a debate on the optimal sequence of treatments. There is …

The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among
the highest in the world. Several targeted agents have been recently approved for the …

Context No head-to-head clinical trials compare contemporary first-line therapies for
metastatic renal cell carcinoma (mRCC). A network meta-analysis provides an approach for …

Purpose: Our understanding of the natural history of renal cell carcinoma, the role of
nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are …

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel
has compiled these clinical guidelines to provide urologists with evidence-based information …

BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

Seven targeted agents have improved the prognosis of advanced renal cell carcinoma
(RCC), but none are effective in the post-nephrectomy adjuvant setting. Among the available …